Pfizer Inc. said on March 1 the company’s vaccine to prevent infections from a bacteria that mainly spreads through hospitals and doctors’ offices and can even prove fatal, failed to meet the main goal of a late-stage study.
AbelsonTaylor promoted Laura Paul to senior account director. According to the full-service health and wellness advertising agency, she will play a lead role in launching a novel treatment for recurrent C. difficile in the expanding area of microbiome therapeutics and will also continue as team leader on two established accounts.
Seres Therapeutics and Nestlé Health Science have teamed up for the joint commercialization of Seres’ investigational oral microbiome treatment for recurrent Clostridioides difficile (C. difficile) infections.
In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.
Somerville, Massachusetts-based Finch Therapeutics closed a $90 million Series D financing, with plans to use the funds to advance the company’s lead candidate CP101 for recurrent C. difficile infection through the final stages of clinical development and regulatory submission.
Finch Therapeutics reported positive topline results from PRISM3, a Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
Rebiotix, based in Roseville, Minnesota, and Ferring Pharmaceuticals, with headquarters in Saint-Prex, Switzerland, announced positive preliminary results from the companies’ ongoing pivotal Phase III trial of RBX2660.
